Benzodiazepines (Psy and mixed indications) updated on 02-10-2025

Tetralogy of Fallot

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15464
R63588		 Blotière - Clonazepam (Other indications), 2019 Tetralogy of Fallot 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No BZD Coexposure: No (among antiseizure medications) 3.30 [0.10;18.40] 1/980   584/1,875,733 585 980
ref
S15593
R64179		 Tinker - BZDs, 2019 Tetralogy of Fallot 1st trimester case control unexposed (general population or NOS) Adjustment: Yes BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) 1.30 [0.70;2.40] 14/95   1,182/12,634 1,196 95
ref
Total 2 studies 1.37 [0.75;2.49] 1,781 1,075
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Blotière - Clonazepam (Other indications), 2019Blotière - Clonazepam, 2019 1 3.30[0.10; 18.40]5859805%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Tinker - BZDs, 2019Tinker - BZDs, 2019 1.30[0.70; 2.40]1,1969595%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate Total (2 studies) I2 = 0% 1.37[0.75; 2.49]1,7811,0750.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Other indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 3.30[0.24; 44.76]585980 -NABlotière - Clonazepam (Other indications), 2019 1 case control studiescase control studies 1.30[0.70; 2.41]1,19695 -NATinker - BZDs, 2019 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.37[0.75; 2.49]1,7811,0750%NABlotière - Clonazepam (Other indications), 2019 Tinker - BZDs, 2019 2 Tags Adjustment   - No  - No 3.30[0.24; 44.76]585980 -NABlotière - Clonazepam (Other indications), 2019 1   - Yes  - Yes 1.30[0.70; 2.41]1,19695 -NATinker - BZDs, 2019 1 BZD Coexposure   - No (among antiseizure medications)  - No (among antiseizure medications) 3.30[0.24; 44.76]585980 -NABlotière - Clonazepam (Other indications), 2019 1   - Yes (with psychiatric (ATD and/or p ...  - Yes (with psychiatric (ATD and/or psychotropics) medications) 1.30[0.70; 2.41]1,19695 -NATinker - BZDs, 2019 1 All studiesAll studies 1.37[0.75; 2.49]1,7811,0750%NABlotière - Clonazepam (Other indications), 2019 Tinker - BZDs, 2019 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.37[0.75; 2.49]1,7811,0750%NABlotière - Clonazepam (Other indications), 2019 Tinker - BZDs, 2019 20.510.01.0